Go to main content
Type 1
Type 2

Omnipod Horizon System to Integrate Freestyle Libre 2, G6, and G7 CGMs

By Eliza Skoler, Rhea Teng, and Albert Cai

Insulet partners with Abbott and Dexcom to develop Omnipod Horizon systems

In a major splash at the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid, Spain, Insulet unveiled partnerships with continuous glucose monitor (CGM) companies Abbott and Dexcom. Insulet announced plans to integrate Abbott’s FreeStyle Libre 2 (still under FDA review) and Dexcom’s G6, and upcoming G7 (launch in 2021), into Insulet’s Omnipod Horizon automated insulin delivery (AID) system (launch in early 2021).

AID systems use CGM and smart algorithms to automatically adjust insulin delivery via pump. The dual-partnerships mean that Horizon will be the first AID system with two CGM partners.

Dexcom and Insulet Partnership

Dexcom’s G6 and upcoming G7 will be combined with Insulet’s AID system to predict blood sugar levels and dose insulin, with the aim of keeping users within their target blood sugar range.

Abbott and Insulet Partnership

Abbott and Insulet announced a similar partnership: they will combine Abbott’s next-generation FreeStyle Libre 2 CGM sensor with the Omnipod Horizon AID system. The FreeStyle Libre 2 system is currently approved in Europe. It is currently under review by the FDA for approval in the US.

What is Omnipod Horizon?

The Omnipod Horizon system uses CGM readings to automatically adjust basal insulin delivery. Insulet’s tubeless insulin delivery pod is a three-day-wear patch pump, which will communicate with a CGM to deliver insulin. Users control the system directly from their smartphone.

As of March 2020, the Omnipod Horizon pivotal trial is paused to fix a software issue; this will delay Insulet’s partnerships with Dexcom and Abbott.